Navigation Links
Dendreon Promotes Dr. Mark Frohlich to Senior Vice President of Clinical Affairs and Chief Medical Officer
Date:12/7/2007

SEATTLE, Dec. 7 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) today announced that the Company has promoted Mark Frohlich, M.D. to the position of senior vice president of clinical affairs and chief medical officer. Dr. Frohlich, a urologic oncologist with over a decade of oncology drug development and patient treatment experience in the public and private sectors, was instrumental to the filing of the company's Biologics License Application (BLA) for PROVENGE(R) (sipuleucel-T) and has also had responsibility for monitoring the progress of the company's ongoing Phase 3 IMPACT trial (D9902B), a pivotal trial for Dendreon, the results of which could support the licensure of PROVENGE. Dr. Frohlich was promoted from the position of vice president of clinical affairs.

"Mark has been an exemplary leader who has led Dendreon's clinical efforts during a very active time for the organization with the ongoing regulatory approval process of PROVENGE -- a process which Mark and the rest of our team remain committed to seeing through to the approval of this promising immunotherapy for prostate cancer," stated Mitchell H. Gold, M.D., president and chief executive officer of Dendreon. "We are fortunate to have someone with Mark's expertise at the helm of our clinical team with the depth of his experience in oncology as well as his direct patient experience."

Prior to joining Dendreon in 2005, Dr. Frohlich was vice president and medical director at Xcyte Therapies where he oversaw its medical affairs operations. At Xcyte, he led the clinical development program for an autologous activated T cell therapy for the treatment of cancer, infection and immunodeficiency. Before that, he was an assistant professor in the Division of Hematology/Oncology at the University of California, San Francisco, where he specialized in urologic oncology and was active in laboratory, translational and clinical research. While at the University of California, San Franc
'/>"/>

SOURCE Dendreon Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Dendreon Announces Webcast Presentation at UBS Life Sciences Conference
3. Dendreon Secures $130 Million Committed Equity Financing Facility
4. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
5. Dendreon Reports Third Quarter 2007 Financial Results
6. Enzyme promotes fat formation
7. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
8. IDM Pharma Names Dr. Jeffrey W. Sherman Chief Medical Officer and Senior Vice President of Research and Development
9. Alba Therapeutics Appoints Dr. Betsy Van Parijs as Its Senior Vice President, Clinical Development and Medical Affairs
10. Senior Research Analyst Richard Evans Joins AVOS Life Sciences
11. Schering-Plough Announces Pricing of Senior Notes Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... -- EPFL and the University of  Geneva ... John P. Donoghue . The American neuroscientist is to ... The new Wyss Center for Bio- and ... , has named as its director one of ... , founder of Brown University,s Institute for Brain Science, ...
(Date:7/10/2014)... Canada (PRWEB) July 10, 2014 ... present in very low abundance and are often ... challenging and time-consuming. , Join presenters Dr. Rowel ... and Dr. John Anders, Head of Quality at ... spectrometer-based approach that can speed detection and quantitation ...
(Date:7/10/2014)... Robert Harman, DVM, Founder and CEO of Vet-Stem, Inc., ... the relaunch of his highly informative blog, now named Stem ... What are Stem Cells ?” Dr. Harman’s purpose for ... the basics of stem cell therapy so that pet owners ... treatment when considering regenerative medicine. , A veterinarian by trade, ...
(Date:7/10/2014)... On July 9 Prime Minister ... Russia,s first national "Industry" award ... is developing a unique project called MabNext . ... number of innovative drugs based on monoclonal antibodies for ... place at the International Exhibition "Innoprom 2014" in Ekaterinburg. ...
Breaking Biology Technology:John P. Donoghue is Taking the Lead at the Wyss Center and is Appointed Professor at EPFL and University of Geneva 2John P. Donoghue is Taking the Lead at the Wyss Center and is Appointed Professor at EPFL and University of Geneva 3Novel Ms Techniques Speed Detection of Biopharmaceutical Product and Process Impurities, New Webinar Hosted by Xtalks 2Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 2Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 3Dmitry Medvedev Presented BIOCAD the First National "Industry" Award 2
... 31 BioCryst,Pharmaceuticals, Inc. (Nasdaq: BCRX ) ... NewsMakers in the Biotech Industry conference in New,York. ... Thursday, September,6, 2007 at 2:00 p.m. Eastern Time ... . The presentation will be archived for seven ...
... FREMONT, Calif., Aug. 30 ARYx Therapeutics, Inc.,announced today ... S-1 with,the Securities and Exchange Commission for a proposed ... of the shares in the proposed,offering will be sold ... will be Morgan Stanley & Co.,Incorporated acting as sole ...
... (Nasdaq: VRNM ), a leading developer of cellulosic ... specialty,enzymes, announced today that Carlos A. Riva, President and ... Cowen and Company Clean,Energy Conference. The presentation is scheduled ... 2007 and will take place at Le Parker Meridien ...
Cached Biology Technology:BioCryst to Present at the BioCentury NewsMakers in the Biotech Industry Conference 2BioCryst to Present at the BioCentury NewsMakers in the Biotech Industry Conference 3ARYx Therapeutics, Inc. Files Registration Statement for Initial Public Offering 2Verenium Corporation to Present at the Upcoming Cowen and Company Clean Energy Conference 2Verenium Corporation to Present at the Upcoming Cowen and Company Clean Energy Conference 3
(Date:7/11/2014)... group members to reduce aggression and gain access to ... grooming activities shows a certain pattern across the day. ... Biology Letters . , Grooming between individuals in ... motives. To be groomed has hygienic benefits and is ... can provide access to infants, mating opportunities and high ...
(Date:7/11/2014)... University, Sweden, have explored two different ways that ... leading to the formation of oxygen molecules in ... the scientific journal Nature Communications . , ... synthetic catalysts for water oxidation, which are key ... direct storage of solar energy in fuels like ...
(Date:7/11/2014)... increased risk of kidney injury related to the use ... mass of HES molecules, according to a report in ... International Anesthesia Research Society (IARS). , The "total mass ... on cultured human renal proximal tubule cells (PTCs), concludes ... of University Hospital Wrzburg, Austria. Other factorssuch as ...
Breaking Biology News(10 mins):Baboons groom early in the day to get benefits later 2Molecular snapshots of oxygen formation in photosynthesis 2In lab studies, hydroxyethyl starch has direct harmful effects on kidney cells 2
... of Illinois at Chicago College of Pharmacy are ... an antipsychotic medication works in adults and children ... Risperidone, a popular "atypical" antipsychotic medication, is used ... bipolar disorder. , Jeffrey Bishop, assistant professor ...
... molecular mechanism underlying the hyperactive high of cocaine. In ... interactions between two types of receiving stations in neurons ... in rats found that when the animals received cocaine, ... tends to grab onto a component of a receptor ...
... demand, Montana State University entomologists are investigating ways ... the entomologists are concluding a two-year study that ... sawfly larvae that tunnel the interior of developing ... master's graduate Godshen Pallipparambil-Robert and undergraduate Melissa Frazier ...
Cached Biology News:Studies look at how genes affect antipsychotic drug response 2Cocaine high caused by interference in neuronal receiving stations 2Rearing an army to save wheat 2Rearing an army to save wheat 3
... MBPK Antibody - Red, 20X ... MBPK antibody at 20X concentration for ... polarization assays. Quality ... 645nm FarRed fluorescence polarization assays. ...
Goat polyclonal to SPFH2 ( Abpromise for all tested applications). Antigen: Synthetic peptide: EDEPLETATKEN, corresponding to C terminal amino acids 328-339 of Human SPFH2 Entrez Gene ID: 11...
alpha/beta-Tubulin Antibody Ship: Hot Store: -20 C...
Anti-Kusabira Orange Monoclonal Antibody Description: 100 g Research Focus: tag Storage: -20C Shipping Temperature: 4C...
Biology Products: